Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that.
A narrow question about NHS criteria, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
This follows post #8 rather than contradicting it.
An update on my earlier NHS criteria post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Narrowing post #9, because the general version has more than one answer.
Distinguishing three things in the NHS criteria discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
Read the full topic (16 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…
|
+62 | 67 | 2.1k | 6mo |
|
MHRA statements, read directly — the long version
On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Asking about MHRA statements directly, because I have read four threads on it and each…
|
2 | 44k | 22mo | |
|
About the UK & Ireland category
MHRA positions, NHS pathways, private prescriptions, and Irish differences. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
|
+3 | 7 | 357 | 3mo |
|
MHRA statements, read directly
MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each…
|
+93 | 101 | 2.2k | 5mo |
|
Irish differences from the UK position
Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Trying to establish the boundary conditions on irish differences. The general…
|
+62 | 66 | 993 | 21mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Irish differences from the UK position — what changed since
Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Irish differences is wrong? I ask…
|
+8 | 12 | 782 | 1d |
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. A narrow question about Labelling requirements for…
|
2 | 1.8k | 2mo | |
|
Follow-up: UK access routes, dated and sourced
On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion. Regional question, dated March 2026, because everything in this category expires. The position differs…
|
+10 | 14 | 27k | 2d |
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…
|
+62 | 67 | 2.1k | 6mo |
|
Pen wastage and its effect on real cost
Pen wastage and its effect on real cost Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on pen wastage, because they…
|
+29 | 33 | 19k | 21mo |